Therefore, patients with BRAF-V600E-mutant CRC, who had higher levels of immune activity, might derive further benefit from the addition of a MEK inhibitor or immunotherapy in combination with BRAF/EGFR inhibition, possibly accounting for the aforementioned findings in the present study. This evidence concerns the gene EGFR and colorectal carcinoma.